Compare Amphastar Pharmaceuticals Inc (AMPH) vs Baxter International Inc (BAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Baxter International Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Baxter International Inc trades at $22.63 (market cap $11.68B). The key difference: Baxter International Inc is far larger — about 14.1× Amphastar Pharmaceuticals Inc's market cap, and Baxter International Inc pays a 0.88% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BAX | |
|---|---|---|
Market Cap | $826.08M | $11.68B |
Sector | Health | Health |
52-Week High | $30.81 | $29.22 |
52-Week Low | $16.87 | $15.80 |
Enterprise Value | $1.22B | $19.35B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% on the day, with a bearish technical signal from moving averages. Recent earnings missed estimates in Q1 2026, with revenue of $171.2 million and adjusted EPS of $0.42 versus $0.70 expected. The company is shifting focus toward proprietary drugs and biosimilars for growth, as noted at recent investor conferences.
Outlook is mixed: valuation ratios appear reasonable with P/E of 11.29 and EV/EBITDA of 6.32, but earnings misses and a Zacks Strong Sell rating highlight near-term risks. The consensus price target of $20.40 suggests modest upside if execution improves, though legal scrutiny and competitive pressures remain concerns.
Baxter International (BAX) trades at $22.57, down 0.22% with a mixed technical outlook showing bullish moving averages but overbought RSI signals. The company faces fundamental challenges with negative net income margins (-9.7%) and ROE (-16.73%) despite recent earnings beats. Analyst consensus leans neutral with 53% hold ratings and a $22.67 price target slightly above current levels. Recent news highlights upcoming Q2 2026 earnings and sustainability initiatives.
BAX presents a turnaround story with attractive valuation metrics (P/S 1.03) but significant profitability concerns. The stock offers limited upside to consensus targets with execution risk remaining high. Key catalysts include Q2 earnings results and operational improvements under new leadership, while persistent margin pressure and high debt levels pose substantial risks to recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →
